Entyvio bests Humira in first ever head-to-head study in ulcerative colitis

9 March 2019

Results from the head-to-head VARSITY study, the first prospective clinical study to directly compare the efficacy and safety of two commonly used biologic therapies in patients with ulcerative colitis, were released today at the 14th Congress of the European Crohn’s and Colitis Organization (ECCO) in Copenhagen, Denmark.

Results showed that Japan pharma major Takeda’s (TYO: 4502) Entyvio (vedolizumab) to be superior to Humira (adalimumab), the world’s biggest selling drug from AbbVie (NYSE: ABBV), in achieving statistically-significant clinical remission (p=0.0061) and mucosal healing (p=0.0005) at week 52 in patients with moderately to severely active ulcerative colitis.

This is an exciting time in the landscape of ulcerative colitis treatment, as head-to-head clinical data has not previously been available to guide treatment decisions around biologic therapies, the company noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK